MedPath
HSA Approval

IRINOTECAN HYDROCHLORIDE ADVAGEN CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML

SIN15701P

IRINOTECAN HYDROCHLORIDE ADVAGEN CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML

IRINOTECAN HYDROCHLORIDE ADVAGEN CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML

May 29, 2019

ADVAGEN PTE. LTD.

ADVAGEN PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantADVAGEN PTE. LTD.
Licence HolderADVAGEN PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01XX19

xl 01 xx 19

Manufacturer Information

ADVAGEN PTE. LTD.

Sichuan Huiyu Pharmaceutical Co., Ltd

Active Ingredients

Irinotecan 17.33 mg/ml eqv Irinotecan Hydrochloride

20 mg/ ml

Irinotecan

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

IRINOTECAN HYDROCHLORIDE ADVAGEN CONCENTRATE FOR SOLUTION FOR INFUSION 20MG/ML - HSA Approval | MedPath